Cyclopharm Limited (CYC.AX)
Cyclopharm Limited operates in the Medical - Devices industry of the Healthcare sector, headquartered in Kingsgrove, NSW, AU. The stock last traded at $0.54, up 0.00% on the session, giving a market capitalisation of $67.3M. Its beta of 0.59 implies it has historically moved less than the broad market.
Cyclopharm Limited is an international enterprise specializing in the production and global distribution of medical devices and radiopharmaceuticals, with operations spanning Asia Pacific, Europe, Canada, and other regions. The company's business activities are structured into two principal divisions: Technegas and Molecular Imaging. Through its Technegas segment, Cyclopharm supplies diagnostic apparatus and accompanying consumables critical for clinicians in the identification of pulmonary embolisms, alongside distributing third-party offerings to the broader diagnostic imaging sector. Conversely, the Molecular Imaging division provides advanced radiopharmaceutical agents essential for medical practitioners diagnosing conditions such as cancer, various neurological disorders, and cardiac diseases. Cyclopharm primarily serves nuclear medicine departments. Established in 1986, the company's corporate headquarters are located in Kingsgrove, Australia.
Cyclopharm Limited is most often compared with the following Healthcare names: